Abstract
THE putative oncogene bcl-2 is juxtaposed to the immunoglobulin heavy chain (Igh) locus1-3 by the t(14;18) chromosomal translocation typical of human follicular B-cell lymphomas4. The bcl-2 gene product (refs 5,6) is not altered by the translocation, but its expression is deregulated6–8, presumably by the Igh enhancer Eµ. Constitutive bcl-2 expression seems to augment cell survival, as infection with a bcl-2 retrovirus enables certain growth factor-dependent mouse cell lines to maintain viability when deprived of factor9,10. Furthermore, high levels of the bcl-2 product can protect human B and T lymphoblasts under stress11,12 and thereby confer a growth advantage12–14. Mice expressing a bcl-2 transgene controlled by the Igh enhancer accumulate small non-cycling B cells which survive unusually well in vitro15–17 but do not show a propensity for spontaneous tumorigenesis15,16. In contrast, an analogous myc transgene, designed to mimic the myc–Igh translocation product typical of Burkitt's lymphoma and rodent plasmacytoma18, promotes B lymphoid cell proliferation and predisposes mice to malignancy in pre-B and B lymphoid cells19-22. Previous experiments have suggested that bcl-2 can cooperate with deregulated myc to improve in vitro growth of pre-B and B cells9,11. Here we describe a marked synergy between bcl-2 and myc in doubly transgenic mice. Eµ–bcl–2/myc mice show hyperproliferation of pre-B and B cells and develop tumours much faster than Eµ–myc mice. Surprisingly, the tumours derive from a cell with the hallmarks of a primitive haemopoietic cell, perhaps a lymphoid-committed stem cell.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C. & Croce, C. M. Science 226, 1097–1099 (1984).
Bakhshi, A. et al. Cell 41, 889–906 (1985).
Cleary, M. L., Smith, S. D. & Sklar, J. Cell 47, 19–28 (1986).
Fukuhara, S., Rowley, J. D., Variakojis, D. & Golomb, H. M. Cancer Res. 39, 3119–3128 (1979).
Tsujimoto, Y. N., Ikegaki, N. & Croce, C. M. Oncogene 2, 3–7 (1987).
Chen-Levy, Z., Nourse, J. & Cleary, M. L. Molec. cell. Biol. 9, 701–710 (1989).
Reed, J. C., Tsujimoto, Y., Alpers, J. D., Croce, C. M. & Howell, P. C. Science 236, 1295–1299 (1987).
Graninger, W. B., Seto, M., Boutain, B., Goldman, P. & Korsmeyer, S. J. J. clin. Invest. 80, 1512–1515 (1987).
Vaux, D. L., Cory, S. & Adams, J. M. Nature 335, 440–442 (1988).
Nunez, G. et al. J. Immun. 144, 3602–3610 (1990).
Tsujimoto, Y. Oncogene 4, 1331–1336 (1989).
Reed, J. C. et al. Proc. natn. Acad. Sci. U.S.A. 87, 3660–3664 (1990).
Reed, J. C., Haldar, S., Cuddy, M. P., Croce, C. M. & Makover, D. Oncogene 4, 1123–1127 (1989).
Nunez, G. et al. Proc. natn. Acad Sci. U.S.A. 86, 4589–4593 (1989).
McDonnell, T. J. et al. Cell 57, 79–88 (1989).
Strasser, A. et al. Curr. Topics Microbiol. Immun. (in the press).
McDonnell, T. J. et al. Molec. cell. Biol. 10, 1901–1907 (1990).
Cory, S. Adv. Cancer Res. 47, 189–234 (1986).
Adams, J. M. et al. Nature 318, 533–538 (1985).
Langdon, W. Y., Harris, A. W., Cory, S. & Adams, J. M. Cell 47, 11–18 (1986).
Harris, A. W. et al. J. exp. Med. 167, 353–371 (1988).
Schmidt, E. V., Pattengale, P. K., Weir, L. & Leder, P. Proc. natn. Acad. Sci. U.S.A. 85, 6047–6051 (1988).
Strasser, A. Eur. J. Immun. 18, 1803–1810 (1988).
Spangrude, G. J., Heimfeld, S. & Weissman, I. L. Science 241, 58–62 (1988).
Fredrickson, G. G. & Basch, R. S. J. exp. Med. 169, 1473–1478 (1989).
Morse, H. C. III et al. J. exp. Med. 165, 920–925 (1987).
Palacios, R. & Steinmetz, M. Cell 41, 727–734 (1985).
Alessandrini, A., Pierce, J. H., Baltimore, D. & Desiderio, S. V. Proc. natn. Acad. Sci. U.S.A. 84, 1799–1803 (1987).
Sakaguchi, N. & Melchers, F. Nature 324, 579–582 (1986).
Schatz, D. G., Oettinger, M. A. & Baltimore, D. Cell 59, 1035–1048 (1989).
Tidmarsh, G. F., Heimfeld, S., Whitlock, C. A., Weissman, I. L. & Müller-Sieburg, C. E. Molec. cell. Biol. 9, 2665–2671 (1989).
Langdon, W. L., Harris, A. W. & Cory, S. Oncogene Res. 3, 271–279 (1988).
Pegoraro, L. et al. Proc. natn. Acad. Sci. U.S.A. 81, 7166–7170 (1984).
Gauwerky, C. E., Haluska, F. G., Tsujimoto, Y., Nowell, P. C. & Croce, C. M. Proc. natn. Acad. Sci. U.S.A. 85, 8548–8552 (1988).
Gauwerky, C. E., Huebner, K., Isobe, M., Nowell, P. C. & Croce, C. M. Proc. natn. Acad. Sci. U.S.A. 86, 8867–8871 (1989).
Aihara, Y., Bühring, H-J., Aihara, M. & Klein, J. Eur. J. Immun. 16, 1391–1399 (1986).
Hariharan, I. K. et al. Molec. cell. Biol. 9, 2798–2805 (1989).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Strasser, A., Harris, A., Bath, M. et al. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348, 331–333 (1990). https://doi.org/10.1038/348331a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/348331a0
This article is cited by
-
Mechanisms of BCL-2 family proteins in mitochondrial apoptosis
Nature Reviews Molecular Cell Biology (2023)
-
MNT suppresses T cell apoptosis via BIM and is critical for T lymphomagenesis
Cell Death & Differentiation (2023)
-
Deletion of the transcriptional regulator TFAP4 accelerates c-MYC-driven lymphomagenesis
Cell Death & Differentiation (2023)
-
microRNA sequencing for biomarker detection in the diagnosis, classification and prognosis of Diffuse Large B Cell Lymphoma
Scientific Reports (2023)
-
BCL-2 protein family: attractive targets for cancer therapy
Apoptosis (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
